Open access · CC-BY
via OpenAlex
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
Arvind Ravi, Matthew D. Hellmann, Monica Arniella, Mark Holton, Samuel S. Freeman, Vivek Naranbhai, Chip Stewart, Ignaty Leshchiner, Jaegil Kim, Yo Akiyama, Aaron T. Griffin, Natalie I. Vokes, Mustafa Sakhi, Vashine Kamesan, Hira Rizvi
Nature Genetics · 2023 · ▲ 192 citations
Abstract
Anti-PD-1/PD-L1 agents have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). To expand our understanding of the molecular features underlying response to checkpoint inhibitors in NSCLC, we describe here the first joint analysis of the Stand Up To Cancer-Mark Foundation cohort, a resource of whole exome and/or RNA sequencing from 393 patients with NSCLC treated with anti-PD-(L)1 therapy, along with matched clinical response annotation. We identify a number of associations between molecular features and outcome, including (1) favorable (for example, ATM altered) and unfavorable (for example, TERT amplified) genomic subgroups, (2) a prominent association between expression of inducible components of the immunoproteasome and response and (3) a dedifferentiated tumor-intrinsic subtype with enhanced response to checkpoint blockade. Taken together, results from this cohort demonstrate the complexity of biological determinants underlying immunotherapy outcomes and reinforce the discovery potential of integrative analysis within large, well-curated, cancer-specific cohorts.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1038/s41588-023-01355-5
- Canonical
- link ↗
- Fetched
- 2026-07-28 MST
Cite this
APA
Ravi, A., Hellmann, M.D., Arniella, M., Holton, M., Freeman, S.S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., Griffin, A.T., Vokes, N.I., Sakhi, M., Kamesan, V., Rizvi, H., Ricciuti, B., Forde, P.M., Anagnostou, V., Riess, J.W., & Gibbons, D.L. (2023). Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. <em>Nature Genetics</em>. https://doi.org/10.1038/s41588-023-01355-5
Vancouver
Ravi A, Hellmann MD, Arniella M, Holton M, Freeman SS, Naranbhai V, et al. Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. Nature Genetics. 2023. doi:10.1038/s41588-023-01355-5.
BibTeX
@article{arvind2023Genomi,
title = {Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer},
author = {Arvind Ravi and Matthew D. Hellmann and Monica Arniella and Mark Holton and Samuel S. Freeman and Vivek Naranbhai and Chip Stewart and Ignaty Leshchiner and Jaegil Kim and Yo Akiyama and Aaron T. Griffin and Natalie I. Vokes and Mustafa Sakhi and Vashine Kamesan and Hira Rizvi and Biagio Ricciuti and Patrick M. Forde and Valsamo Anagnostou and Jonathan W. Riess and Don L. Gibbons and Nathan A. Pennell and Vamsidhar Velcheti and Subba R. Digumarthy and Mari Mino–Kenudson and Andrea Califano},
journal = {Nature Genetics},
year = {2023},
doi = {10.1038/s41588-023-01355-5},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Southern Denmark 2018
Open access · US-GOV
The Impact of Age and Comorbidity on Effect of Treatment, Adverse Effects and Quality of Life in Danish Lung Cancer Patients Receiving Immunotherapy
npj Aging 2026
Open access · CC-BY
Aging-related transcriptomic signatures associated with recurrence following resection of stage I lung adenocarcinoma
Genes 2017
Open access · CC-BY
The Intra-S Checkpoint Responses to DNA Damage
biorxiv 2024
Preprint · CC-BY
Molecular mechanisms underlying the modulation of T-cell proliferation and cytotoxicity by immobilized CCL21 and ICAM1
Nature Cancer 2023
Preprint · OA
Cancer cell plasticity during tumor progression, metastasis and response to therapy
Frontiers in Immunology 2024
Open access · CC-BY